{
    "id": "dbpedia_8095_0",
    "rank": 9,
    "data": {
        "url": "https://www.linkedin.com/posts/lsm-lv_olainfarm-rebranded-as-olpha-activity-7209646863585599489-qQs2",
        "read_more_link": "",
        "language": "en",
        "title": "LSM.lv on LinkedIn: Olainfarm rebranded as Olpha",
        "top_image": "https://media.licdn.com/dms/image/v2/D4D10AQHpn-hGsnr21w/image-shrink_1280/image-shrink_1280/0/1718913760785?e=2147483647&v=beta&t=3eOauSYMf_Npl6OU_0W0bjJP8eGKwC954cAfhKw9eWU",
        "meta_img": "https://media.licdn.com/dms/image/v2/D4D10AQHpn-hGsnr21w/image-shrink_1280/image-shrink_1280/0/1718913760785?e=2147483647&v=beta&t=3eOauSYMf_Npl6OU_0W0bjJP8eGKwC954cAfhKw9eWU",
        "images": [
            "https://media.licdn.com/dms/image/v2/C4D1BAQHmaJI79oeNgw/company-background_10000/company-background_10000/0/1643893718470/lsm_lv_cover?e=2147483647&v=beta&t=3mn4eGzW-1iON81wr451dwtPCgGCZ-fkz9qTb9TeAko"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "LSM.lv"
        ],
        "publish_date": "2024-06-20T20:02:41.011000+00:00",
        "summary": "",
        "meta_description": "On Wednesday, June 19, the Latvian pharmaceutical company and drug manufacturer Olainfarm AS announced a rebranding to Olpha Global.",
        "meta_lang": "en",
        "meta_favicon": "https://static.licdn.com/aero-v1/sc/h/al2o9zrvru7aqj8e1x2rzsrca",
        "meta_site_name": "",
        "canonical_link": "https://www.linkedin.com/posts/lsm-lv_olainfarm-rebranded-as-olpha-activity-7209646863585599489-qQs2",
        "text": "ðŸ“ˆ Pharmaceutical #promotion activity in #Ukraine in the first 9 months of 2023 ðŸ“Š According to the #PromoTest project of #ProximaResearch, the number of mentions of the promotion of #pharmacy products from healthcare professionals increased by 34.8% compared to the same period of the previous year. This is 2.9% less than in the pre-war 2021 ðŸ“œ In September 2023, the share of mentions of prescription #drug promotion among all mentions of drug promotion reached 51.3%, indicating that pharmaceutical companies are more actively promoting their #prescription drugs, which are traditionally promoted to physicians ðŸ‘¨âš•ï¸ Personal #visits by #medical representatives remain the main channel of promotion ðŸ¥ Among pharmaceutical companies, Teva, Acino, and Berlin-Chemie are the leaders in terms of the number of mentions of promotion ðŸ’Š Among drug brands, the leading positions are occupied by Olfen, Sumamed, Decatylen and No-Spa ðŸ“Ž Full material is already on the website: http://surl.li/mqrhp #pharma #pharmxplorer #analytics #ProximaPromoTest\n\nThe rules for generic drug pricing in provincial/territorial programs in Canada have been modified. The pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA) have agreed to a new three-year pricing scheme (with the option of an extension for a further two years) for generic drugs, effective 1st October 2023. The new agreement adds Quebec to the scheme, amends the Tiered Pricing Framework (TPF), removes two drugs (famciclovir and minocycline) from the pan-Canadian Select Molecules list and adds â€œnon-formulary benefits.â€ The TPF applies to any generic drug where the current or previously available brand reference product was eligible for reimbursement by any pCPA jurisdiction. The new agreement introduces changes to Tier 1 of the TPF, which comprises single-source generic products. From 1st October 2023, the price will be cut to 55% of the brand reference price three months after the onset of generic competition. There are no changes to tiers 2 or 3. The TPF will apply to new generics that are not formulary benefits but are â€œpublicly funded through a defined and transparent public program.â€ As of 1st October 2023, new generics funded through the Ontario Exceptional Access Program will also be assessed through the TPF. Additional â€œdefined drug programsâ€ in other jurisdictions may qualify for inclusion in the TPF in the future. #Canada #generics\n\nEurasian Pharma Awards 2023: Olainfarm and Meros Pharm are the winners in the nomination â€œPartnership of the Yearâ€ In 2023 in the competition for the Eurasian Pharma Awards in the nomination â€œPartnership of the Yearâ€ the award was presented to Olainfarm and Meros Pharm. The transformation of collaboration between Olainfarm, a leading pharmaceutical company in the Baltics, and Meros Pharm, a leader in pharmaceutical distribution in Uzbekistan, along with increased investments in product promotion and improvements in both international and local logistics, has yielded tangible results that allow to develop ambitious plans for the future. The exclusive agreement has ensured the availability of Olainfarm products in over 4,000 pharmacies and has led to a 65% increase in sales compared to the previous year. Elena Bushberg, Executive Director of Olainfarm, highlighted: Â«As a proverb says a tree is held by its roots, and a person is held by their family and heritage. I would add that success in business is held by good partnersÂ». Learn more >> https://lnkd.in/em2a6fNM #EurasianPharmaAwards #GlobalPharmaLeadersClub #Pharma #conferences #Uzbekistan #Tashkent #Samarkand #EurasianPharmaceuticalSummit #awards\n\nEurasian Pharma Awards 2023: Olainfarm and Meros Pharm are the winners in the nomination â€œPartnership of the Yearâ€ In 2023 in the competition for the Eurasian Pharma Awards in the nomination â€œPartnership of the Yearâ€ the award was presented to Olainfarm and Meros Pharm. The transformation of collaboration between Olainfarm, a leading pharmaceutical company in the Baltics, and Meros Pharm, a leader in pharmaceutical distribution in Uzbekistan, along with increased investments in product promotion and improvements in both international and local logistics, has yielded tangible results that allow to develop ambitious plans for the future. The exclusive agreement has ensured the availability of Olainfarm products in over 4,000 pharmacies and has led to a 65% increase in sales compared to the previous year. Elena Bushberg, Executive Director of Olainfarm, highlighted: Â«As a proverb says a tree is held by its roots, and a person is held by their family and heritage. I would add that success in business is held by good partnersÂ». Learn more >> https://lnkd.in/em2a6fNM #EurasianPharmaAwards #GlobalPharmaLeadersClub #Pharma #conferences #Uzbekistan #Tashkent #Samarkand #EurasianPharmaceuticalSummit #awards\n\nðŸ”¬ Arvato Systems strengthens connection to the pharmaceutical industry! ðŸ”¬ The Bundesverband der Arzneimittel-Hersteller e.V. (BAH) (German Association of Pharmaceutical Manufacturers) offers a unique platform to strengthen our expertise for digital solutions in the pharmaceutical industry and to position them where they are heard and needed. As a new member of the association, Arvato Systems is given the opportunity to deepen its understanding of the industry's needs and to align its service portfolio specifically with them. You can read more details in our brand new press release â¬‡ï¸ #PharmaceuticalIndustry #PharmaIT\n\nDeveloping and manufacturing drug products containing highly potent active pharmaceutical ingredients (HPAPIs) is in demand. The predicted growth in oncology research is set to continue, and with a high proportion of therapies being small molecules containing highly potent actives, the trend in outsourcing to a specialist CDMO partner for drug product manufacturing is critical. Dr. Rebecca Coutts of PCI Pharma Services Manufacturing Center of Excellence highlights the importance of selecting the right partner for the development, manufacture, packaging, and commercialization of oncology products containing highly potent active pharmaceutical ingredients. Read the full article as published in PHARMAnetwork Magazine: https://lnkd.in/d3RBm4Qr #DrugProductManufacturing #HPAPI #CDMO #LetsTalkFuture\n\nEurasian Pharma Awards 2023: Olainfarm and Meros Pharm are the winners in the nomination â€œPartnership of the Yearâ€ In 2023 in the competition for the Eurasian Pharma Awards in the nomination â€œPartnership of the Yearâ€ the award was presented to Olainfarm and Meros Pharm. The transformation of collaboration between Olainfarm, a leading pharmaceutical company in the Baltics, and Meros Pharm, a leader in pharmaceutical distribution in Uzbekistan, along with increased investments in product promotion and improvements in both international and local logistics, has yielded tangible results that allow to develop ambitious plans for the future. The exclusive agreement has ensured the availability of Olainfarm products in over 4,000 pharmacies and has led to a 65% increase in sales compared to the previous year. Elena Bushberg, Executive Director of Olainfarm, highlighted: Â«As a proverb says a tree is held by its roots, and a person is held by their family and heritage. I would add that success in business is held by good partnersÂ». Learn more >> https://lnkd.in/eadShBi8 #EurasianPharmaAwards #GlobalPharmaLeadersClub #Pharma #conferences #Uzbekistan #Tashkent #Samarkand #EurasianPharmaceuticalSummit #awards"
    }
}